An X post from Elon Musk on Wednesday highlighted Tesla (TSLA) CEO's newfound preference for Eli Lilly's (NYSE:LLY) weight loss therapy Mounjaro over Novo Nordisk's (NVO) rival product Ozempic.
Known as tirzepatide and semaglutide in generic terms, Mounjaro and Ozempic belong to a new class of diabetes drugs called GLP-1s, marketed as Zepbound and Wegovy for weight loss, respectively.
"Like Cocaine Bear, but Santa and Ozempic!" Musk said, dressed as Santa Claus in a post titled "Ozempic Santa."
In response to a question on the specific product he uses, Musk, who also heads the space exploration company SpaceX (SPACE), noted, "Technically, Mounjaro, but that doesn't have the same ring to it."
"Mounjaro seems to have fewer side effects and be more effective," he explained. In 2022, Musk, the incoming co-chair of President-elect Donald Trump's newly created Department of Government Efficiency, credited Wegovy for his weight loss.
Given his unwavering support for GLP-1s, Musk seems to be at odds with Trump's pick for health secretary, Robert F. Kennedy Jr., who has long advocated for dietary control over drugs to fight America's obesity epidemic.